Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis Plans To Buy Back Speedel For $880 Million

Jul 10 2008

• By Shirley Haley

Related Content

Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension

Mar 06 2007

Speedel CEO Alice Huxley: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Nov 27 2007

Speedel CEO Alice Huxley: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Nov 21 2007

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window